Literature DB >> 22511414

Opportunity lost and found: Any easy way to improve outcomes for prostate cancer patients in the postoperative setting?

D Andrew Loblaw1.   

Abstract

Entities:  

Year:  2012        PMID： 22511414      PMCID： PMC3328561          DOI： 10.5489/cuaj.12061

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  11 in total

Review 1.  Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis.

Authors:  Scott C Morgan; Tricia S Waldron; Libni Eapen; Linda A Mayhew; Eric Winquist; Himu Lukka
Journal:  Radiother Oncol       Date:  2008-05-22       Impact factor: 6.280

2.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).

Authors:  Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

3.  Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence.

Authors:  Tim J Kruser; David F Jarrard; Andrew K Graf; Sean P Hedican; David R Paolone; John D Wegenke; Glenn Liu; Heather M Geye; Mark A Ritter
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

4.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Hans Garmo; Jennifer R Stark; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

5.  The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia.

Authors:  Scott Tyldesley; Michael Peacock; James W Morris; Alan So; Charmaine Kim-Sing; Jill Quirt; Michael Carter; Tom Pickles
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

6.  Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

Authors:  Thomas Wiegel; Dirk Bottke; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Norman Willich; Axel Semjonow; Rainer Souchon; Michael Stöckle; Christian Rübe; Lothar Weissbach; Peter Althaus; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  J Clin Oncol       Date:  2009-05-11       Impact factor: 44.544

7.  Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; Michael W Kattan; Thomas M Pisansky; Kevin M Slawin; Eric A Klein; Mitchell S Anscher; Jeff M Michalski; Howard M Sandler; Daniel W Lin; Jeffrey D Forman; Michael J Zelefsky; Larry L Kestin; Claus G Roehrborn; Charles N Catton; Theodore L DeWeese; Stanley L Liauw; Richard K Valicenti; Deborah A Kuban; Alan Pollack
Journal:  J Clin Oncol       Date:  2007-05-20       Impact factor: 44.544

8.  Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794.

Authors:  Gregory P Swanson; Michael A Hussey; Catherine M Tangen; Joseph Chin; Edward Messing; Edith Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

9.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  J Urol       Date:  2009-01-23       Impact factor: 7.450

10.  Hypofractionation for prostate cancer.

Authors:  Mark Ritter; Jeffrey Forman; Patrick Kupelian; Colleen Lawton; Daniel Petereit
Journal:  Cancer J       Date:  2009 Jan-Feb       Impact factor: 3.360
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.